Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Lyra Therapeutics, Inc. (LYRA) reported a Q3 loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.23 loss. This is an improvement from the $0.27 loss per share reported a year ago.
November 12, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lyra Therapeutics reported a Q3 loss of $0.18 per share, beating the Zacks Consensus Estimate of a $0.23 loss. This is an improvement from last year's $0.27 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on LYRA's stock price. The improvement from the previous year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100